Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Kusanationon Jul 20, 2020 4:52pm

248 Views

Post# 31292663

RE:RE:A Quick Question

Very well put and totally makes sense. I hope good news comes out of the SH letter that indicates a bright future.

if you recall the nationwide conference call, Dan did say that "partners were waiting for these phase 2B results and this was what they wanted to see". He was referring to partners in South Korea. So MUGS when you talk about what the meeting has been looking like, could it have something to do with this? Could it be that something is on the verge of concluding considering that this partner was waiting for these phase 2B results as Dan said? Thoughts?

Bullboard Posts

The top 10 Canadian medical stocks